Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1996 1
1997 2
2001 2
2004 1
2005 1
2006 3
2007 3
2008 5
2009 5
2010 2
2011 6
2012 6
2013 6
2014 7
2015 9
2016 6
2017 2
2018 1
2019 2
2020 3
2021 2
2022 5
2023 7
2024 1
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O; International Breast Cancer Study Group; POSITIVE Trial Collaborators. Partridge AH, et al. N Engl J Med. 2023 May 4;388(18):1645-1656. doi: 10.1056/NEJMoa2212856. N Engl J Med. 2023. PMID: 37133584 Free PMC article. Clinical Trial.
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L, Buttiron Webber T, Fava M, Briata IM, Giordano L, Digennaro M, Cortesi L, Falcini F, Serra P, Avino F, Millo F, Cagossi K, Gallerani E, De Simone A, Cariello A, Aprile G, Renne M, Bonanni B, DeCensi A. Lazzeroni M, et al. Among authors: gallerani e. J Clin Oncol. 2023 Jun 10;41(17):3116-3121. doi: 10.1200/JCO.22.02900. Epub 2023 Mar 14. J Clin Oncol. 2023. PMID: 36917758 Clinical Trial.
How's your waiting list?
Gulino V, Ricci B, Russo S, Nigro M, Gallerani E, Lombardo E, Perger P, Campagna A, Buccioli M. Gulino V, et al. Among authors: gallerani e. Ann Ig. 2025 Nov-Dec;37(6):797-806. doi: 10.7416/ai.2025.2701. Epub 2025 Apr 29. Ann Ig. 2025. PMID: 40299542 Free article.
Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19.
Dallan B, Proietto D, De Laurentis M, Gallerani E, Martino M, Ghisellini S, Zurlo A, Volpato S, Govoni B, Borghesi M, Albanese V, Appay V, Bonnini S, Llewellyn-Lacey S, Pacifico S, Grumiro L, Brandolini M, Semprini S, Sambri V, Ladell K, Parry HM, Moss PAH, Price DA; RIV Study Group; Caputo A, Gavioli R, Nicoli F. Dallan B, et al. Among authors: gallerani e. Nat Aging. 2024 Aug;4(8):1121-1136. doi: 10.1038/s43587-024-00644-w. Epub 2024 Jun 25. Nat Aging. 2024. PMID: 38918602
Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase III trial in non-invasive breast cancer.
Carbone A, Oliva M, Puntoni M, Guerrieri-Gonzaga A, Briata IM, Lazzeroni M, Serrano D, Giordano L, Digennaro M, Cortesi L, Millo F, Cagossi K, Aprile G, Serra P, Gallerani E, Bonanni B, DeCensi A. Carbone A, et al. Among authors: gallerani e. J Natl Cancer Inst. 2025 Aug 28:djaf250. doi: 10.1093/jnci/djaf250. Online ahead of print. J Natl Cancer Inst. 2025. PMID: 40880294
Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial.
Johansson H, Macis D, Oliva M, Puntoni M, Blondeaux E, Guerrieri-Gonzaga A, Aristarco V, Briata IM, Buttiron-Webber T, Boni L, Lazzeroni M, Serrano D, Giordano L, Digennaro M, Cortesi L, Millo F, Cagossi K, Aprile G, Falcini F, Gallerani E, Bonanni B, DeCensi A. Johansson H, et al. Among authors: gallerani e. Clin Cancer Res. 2025 May 15;31(10):1841-1846. doi: 10.1158/1078-0432.CCR-24-2987. Clin Cancer Res. 2025. PMID: 40293268 Clinical Trial.
Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence.
Zambelli A, Gallerani E, Garrone O, Pedersini R, Rota Caremoli E, Sagrada P, Sala E, Cazzaniga ME. Zambelli A, et al. Among authors: gallerani e. Crit Rev Oncol Hematol. 2023 Nov;191:104104. doi: 10.1016/j.critrevonc.2023.104104. Epub 2023 Sep 1. Crit Rev Oncol Hematol. 2023. PMID: 37659765 Free article. Review.
Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.
Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD; International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Regan MM, et al. Breast Cancer Res. 2011 May 26;13(3):209. doi: 10.1186/bcr2837. Breast Cancer Res. 2011. PMID: 21635709 Free PMC article. Review.
81 results